These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34559346)

  • 1. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
    Dev R; Zhong LL; Zarifa A; Albittar AA; Rubin L; Liu S; Yap TA; Dalal S; Hui D; Karp DD; Tsimberidou AM; Piha-Paul SA; Ahnert JR; Fu S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2022 Feb; 40(1):124-133. PubMed ID: 34559346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
    Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
    Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM; Nagy CK; Gray SE
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
    Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
    Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
    Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
    Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
    Yeo W; Lau TK; Li L; Lai KT; Pang E; Cheung M; Chan VT; Wong A; Soo WM; Yeung VT; Tse T; Lam DC; Yeung EW; Ng KP; Tang NL; Tong M; Suen JJ; Mo FK
    Breast; 2020 Apr; 50():30-38. PubMed ID: 31978815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
    Dulal S; Paudel BD; Neupane P; Shah A; Acharya B; Poudyal BS; Shilpakar R; Wood LA
    J Glob Oncol; 2019 Apr; 5():1-6. PubMed ID: 31013182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
    Bosnjak SM; Dimitrijevic J; Djordjevic F
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin.
    Mehra N; Christopher V; Dhanushkodi M; Radhakrishnan V; Ganesan TS; Ganesharajah S; Sagar TG; Ganesan P
    Int J Clin Pharm; 2020 Apr; 42(2):662-666. PubMed ID: 32152887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Mukhopadhyay S; Dutta P; Banerjee S; Bhattacharya B; Biswas S; M Navari R
    Future Oncol; 2021 Jun; 17(16):2041-2056. PubMed ID: 33792376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
    Passik SD; Navari RM; Jung SH; Nagy C; Vinson J; Kirsh KL; Loehrer P
    Cancer Invest; 2004; 22(3):383-8. PubMed ID: 15493359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.
    Kawazoe H; Uozumi R; Murakami A; Yamashita M; Kobayashi-Taguchi K; Kusakabe E; Yamasawa H; Yakushijin Y; Nakamura T; Kamei Y
    Sci Rep; 2018 Nov; 8(1):16232. PubMed ID: 30389996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
    Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
    Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
    Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.